ReviewDigestive diseases and sciences2015
Multi-target stool DNA test: a new high bar for noninvasive screening.
Review in Digestive diseases and sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 66 citations in OpenAlex.
- Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA.Clinical epigenetics · 2019Trial
- Cracking the Code of Colorectal Cancer Screening: An Overview With a Focus on Current and Emerging Screening Methods.Cureus · 2025Review
- Survival Benefit and Cost Effectiveness of a Future Blood-Based Diagnostic Test to Detect Cerebral Aneurysm Formation.Stroke (Hoboken, N.J.) · 2024Article
- Review
- Diagnostic value of methylated branched chain amino acid transaminase 1/IKAROS family zinc finger 1 for colorectal cancer.World journal of gastroenterology · 2023Article
- HypermethylatedFrontiers in oncology · 2023Article
- Reducing disparities and achieving health equity in colorectal cancer screening.Techniques and innovations in gastrointestinal endoscopy · 2023Article
- Current and future applications of biomarkers in samples collected through minimally invasive methods for cancer medicine and population-based research.American journal of human biology : the official journal of the Human Biology Council · 2022Review
- Analysis of blood markers for early colorectal cancer diagnosis.Journal of gastrointestinal oncology · 2022Article
- Review
- Circulating cell-free DNA for cancer early detection.Innovation (Cambridge (Mass.)) · 2022Review
- Novel multiplex stool-based assay for the detection of early-stage colon cancer in a Chinese population.World journal of gastroenterology · 2022Article
- A New Risk-Scoring System for Colorectal Cancer and Polyp Screening by Turkish Colorectal Cancer and Polyp Study Group.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022Article
- Screening for Colorectal Cancer Leading into a New Decade: The "Roaring '20s" for Epigenetic Biomarkers?Current oncology (Toronto, Ont.) · 2021Review
- A fecal-based test for the detection of advanced adenoma and colorectal cancer: a case-control and screening cohort study.BMC medicine · 2021Article
- Multiple Biomarker-Combined Screening for Colorectal Cancer Based on Bisulfate Conversion-Free Detection of Fecal DNA Methylation.BioMed research international · 2021Article
- Screening and diagnosis of colorectal cancer and advanced adenoma by Bionic Glycome method and machine learning.American journal of cancer research · 2021Article
- Non-Invasive Colorectal Cancer Screening: An Overview.Gastrointestinal tumors · 2020Review
- Fecal DNA Testing of TWIST1 Methylation Identifies Patients With Advanced Colorectal Adenoma Missed by Fecal Immunochemical Test for Hemoglobin.Clinical and translational gastroenterology · 2020Article
- Detection of Fusobacterium nucleatum in stool and colonic tissues from Norwegian colorectal cancer patients.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stool DNA testing has evolved into what is now a highly accurate and well-validated test for the screen detection of colorectal neoplasia. An optimized and automated multi-target stool DNA test (MT-sDNA) has achieved the same high point-sensitivities as reported for colonoscopy and significantly higher sensitivity than by fecal immunochemical blood testing for detection of early-stage cancer and advanced precancer. Thus, MT-sDNA sets a new high criterion standard for the noninvasive screen detection of colorectal neoplasia. With clinical application, MT-sDNA has potential to meaningfully address current gaps in our approach to CRC screening through benefits of its high accuracy on screening effectiveness, user-friendly features on patient compliance, and easy mail-out distribution on test access. The US Food and Drug Administration and Center for Medicaid and Medicare Services have recently completed their parallel reviews of MT-sDNA, which has just become available for clinical use. This review summarizes the recent clinical validation data on MT-sDNA, addresses central clinical questions at this front end of implementation, and touches on innovative future applications of stool DNA testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.